DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention

Information source: Shenyang Northern Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ischemic Heart Disease; Acute Coronary Syndromes

Intervention: cilostazol in addition to aspirin and clopidogrel (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Shenyang Northern Hospital

Official(s) and/or principal investigator(s):
Yaling Han, M.D., Principal Investigator, Affiliation: Shenyang Northern Hospital

Summary

Effects of dual antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention has been proven. However, patients with low response to those agents are reported be associated with adverse clinical outcomes. We suppose that optimized antiplatelet therapy for individual patients based on platelet function assay may improve long-term outcomes especially in patients with high risk of thrombosis. In this prospective randomized study, patients in control group all receive standard dual antiplatelet therapy, and patients in optimized group receive different antiplatelet therapy according to risk stratification.

Clinical Details

Official title: Pilot Study of Personal Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Major adverse cardiac and cerebral events at 1 year

Secondary outcome: Hemorrhage events at 1 year

Eligibility

Minimum age: 35 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- non-ST-segment elevated acute coronary syndromes

- patients undergoing selective or emergent PCI

Exclusion Criteria:

- administration of clopidogrel or ticlopidine within 2 weeks

- ST-segment elevated myocardial infarction

- contraindications of antiplatelet therapy

- history of intracranial bleeding

- known bleeding disorders

- severe liver or kidney disease

Locations and Contacts

Northern Hospital, Shenyang, Liaoning 110016, China
Additional Information

Starting date: June 2006
Last updated: October 13, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017